Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility

Affiliations

Review

M Lièvre et al. BMJ. 2001.

. 2001 Mar 10;322(7286):603-5.

doi: 10.1136/bmj.322.7286.603.

¹ Clinical Pharmacology Unit, Faculté de Médecine Laënnec, BP 8071, 69376 Lyons Cedex 08, France.

No abstract available

Comment in

Societal responsibilities of clinical trial sponsors. Lack of commercial pay off is not a legitimate reason for stopping a trial.
Evans S, Pocock S. Evans S, et al. BMJ. 2001 Mar 10;322(7286):569-70. doi: 10.1136/bmj.322.7286.569. BMJ. 2001. PMID: 11238141 Free PMC article. No abstract available.
Commentary: Early discontinuation violates Helsinki principles.
Boyd K. Boyd K. BMJ. 2001 Mar 10;322(7286):605-6. BMJ. 2001. PMID: 11269247 No abstract available.
Responsibilities of sponsors are limited in premature discontinuation of trials.
Ashcroft R. Ashcroft R. BMJ. 2001 Jul 7;323(7303):53. BMJ. 2001. PMID: 11464837 Free PMC article. No abstract available.

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307. - PubMed
1. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615–1622. - PubMed
1. Fey R, Pearson N. Statins and coronary heart disease. Lancet. 1996;347:1389–1390. - PubMed
1. Muldoon MF, Criqui MH. The emerging role of statins in the prevention of coronary heart disease. BMJ. 1997;315:1554–1555. - PMC - PubMed
1. Ulrich S, Hingorani AD, Martin J, Vallance P. What is the optimal age for starting lipid lowering treatment? A mathematical model. BMJ. 2000;320:1134–1140. - PMC - PubMed